Skip to main content

Advertisement

Table 3 Effect sizes and standardized response means across studies

From: Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

  Effect size Standardized response mean
OPAL Broaden OPAL Beyond OPAL Broaden OPAL Beyond
Tofacitinib 5 mg BID N = 68 Tofacitinib 10 mg BID N = 62 Adalimumab 40 mg SC Q2W N = 66 Tofacitinib 5 mg BID N = 64 Tofacitinib 10 mg BID N = 62 Tofacitinib 5 mg BID N = 68 Tofacitinib 10 mg BID N = 62 Adalimumab 40 mg SC Q2W N = 66 Tofacitinib 5 mg BID N = 64 Tofacitinib 10 mg BID N = 62
Month 3
 PASDAS 1.73 2.40 1.69 1.53 1.84 1.42 1.75 1.73 1.26 1.53
 DAPSA 0.90 1.23 1.05 0.81 0.84 1.05 1.25 1.47 0.94 1.15
 CPDAI 1.03 1.53 1.05 1.41 1.45 0.89 1.27 1.11 1.11 1.49
 DAS28–3(CRP) 1.47 1.77 1.37 1.07 1.16 1.25 1.46 1.50 1.14 1.29
Month 6
 PASDAS 2.17 2.81 1.98 1.88 2.10 1.76 2.11 1.64 1.49 1.74
 DAPSA 1.15 1.43 1.24 0.97 0.92 1.18 1.34 1.43 1.11 0.94
 CPDAI 1.53 1.88 1.44 1.65 1.75 1.52 1.52 1.25 1.23 1.55
 DAS28–3(CRP) 1.93 2.11 1.68 1.34 1.23 1.47 1.68 1.79 1.43 1.28
Month 12
 PASDAS 2.51 3.05 2.07 2.10 2.21 1.60
 DAPSA 1.50 1.57 1.30 1.60 1.41 1.36
 CPDAI 1.95 2.12 1.59 1.59 1.64 1.33
 DAS28–3(CRP) 2.25 2.18 1.77 1.69 1.65 1.71
  1. N = number of patients in the full analysis set with baseline psoriasis body surface area affected greater than or equal to 3% and with no missing values for any of the composite endpoints at baseline and months 3, 6, and 12 (OPAL Broaden only for month 12). This subset of patients was used for the calculation of effect sizes and standardized response means
  2. Abbreviations: BID twice daily, CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity Index for Psoriatic Arthritis, DAS28–3(CRP) 3-component Disease Activity Score using 28 joints with C-reactive protein, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease Activity Score, Q2W once every 2 weeks, SC subcutaneous